Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 1

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 3(3)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04182100Phase 2Completed

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

Role: lead

NCT06002490Phase 3Completed

A Study to Evaluate P1101 in Japanese PV Patients

Role: lead

NCT04655092Phase 3Recruiting

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Role: lead

NCT05231044Phase 3Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp

Role: collaborator

NCT05245578Phase 1Completed

Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects

Role: collaborator

NCT03546465Phase 1Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects

Role: lead

All 6 trials loaded